BioSpace News Archive

PharmaCyte Biotech, Inc. provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration for guidance on further development of the technology.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”) announced today the list of events it has chosen to exhibit at or attend during November, 2023, which strategically align with its mission of increasing accessibility of affordable gold-standard PCR diagnostics around the world.

Curative Biotechnology Inc. today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann.

Cordis has announced enrollment of the first patient in its SELUTION4DeNovo IDE trial, the coronary de novo study for SELUTION SLR™ Drug-Eluting Balloon (DEB), the company’s novel sirolimus-eluting balloon.

Novavax, Inc. (Nasdaq: NVAX) today announced that the Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been recommended for approval for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older in the European Union by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.

Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced a poster presentation at the upcoming Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC) 2023, taking place November 1-5, 2023 in San Diego, California.

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2023 38th Annual Meeting November 3-5, 2023 in San Diego, CA.

Immunitas Therapeutics (“Immunitas”) today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting.

Alphatec Holdings, Inc. announced that the successful close of a $150 million secondary offering on October 27, 2023, positions the Company to accelerate investment in the revenue-generating assets required to capitalize on industry disruption.